Rapamycin Super-Saturated Nanocarriers via Surfactant Mediation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic nanocarriers with rapamycin often face challenges in achieving stable, super-saturated concentrations, which are crucial for inducing durable immune tolerance, and they may not be initially sterile filterable due to rapamycin aggregation.
Innovation Solution
The development of synthetic nanocarriers comprising a hydrophobic polyester carrier material and rapamycin, where the rapamycin is present in a stable, super-saturated amount less than 50 weight % based on the weight of the hydrophobic polyester carrier material, and the use of non-ionic surfactants with HLB values less than or equal to 10 to stabilize the rapamycin and enhance filterability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rapamycin concentration is increased to achieve super-saturated state for durable immune tolerance, then immune tolerance efficacy is improved, but rapamycin aggregation occurs causing poor filterability
Solution Approach 1:
The patent introduces a surfactant as an intermediary substance to mediate between rapamycin and the carrier material. The surfactant molecules intercalate between rapamycin molecules, preventing aggregation while maintaining super-saturated concentrations. This resolves the contradiction by enabling high rapamycin loading (improving immune tolerance) while the surfactant prevents precipitation (maintaining filterability).
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation system by adjusting surfactant concentration, hydrophobic polyester composition, and processing conditions. These parameter changes enable the system to maintain rapamycin in a stable super-saturated state without aggregation, simultaneously achieving high efficacy and good manufacturability.
2Duration of action of stationary object
If rapamycin concentration is increased to exceed solubility limit, then immune tolerance durability is improved, but rapamycin precipitates causing non-filterable suspension
Solution Approach 1:
The surfactant acts as a mediator that allows rapamycin to exceed its solubility limit without precipitating. The surfactant-rapamycin-carrier complex maintains molecular dispersion even at super-saturated concentrations, enabling both durable immune tolerance and sterile filterability through 0.22 μm filters.
Solution Approach 2:
The patent creates a composite formulation system comprising hydrophobic polyester carrier material, rapamycin, and surfactant. This composite material system has emergent properties where the combination enables super-saturated rapamycin loading while maintaining filterability, which neither component could achieve alone.
3Ease of manufacture
If conventional nanocarrier formulations are used, then manufacturing is simpler, but stable super-saturated rapamycin concentration cannot be achieved
Solution Approach 1:
The patent modifies key formulation parameters including adding surfactant components, adjusting hydrophobic polyester composition, and optimizing processing conditions. These parameter changes transform the formulation from unstable to stable while maintaining relative manufacturing simplicity, achieving super-saturated rapamycin concentrations that remain stable over time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These synthetic nanocarriers achieve more durable antigen-specific immune tolerance and are initially sterile filterable, demonstrating improved stability and efficacy compared to conventional formulations.
Implementation Method 1
the use of non-ionic surfactants with HLB values less than or equal to 10 to stabilize the rapamycin
Implementation Method 2
rapamycin that is in a stable, super-saturated amount
Data Source
AI summary
Disclosed are compositions and methods that provide synthetic nanocarriers that comprise hydrophobic polyester carrier material and rapamycin that is in a stable, super-saturated amount. In some embodiments, the synthetic nanocarriers are also initially sterile filterable. In other embodiments, the rapamycin is present in the synthetic nanocarrier compositions in an amount that is less than 50 weight % rapamycin/hydrophobic polyester carrier material in the composition.